My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Ixazomib citrate (MLN 9708; Ninlaro)
    Ixazomib citrate (MLN 9708; Ninlaro)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0687
    CAS #: 1201902-80-8Purity ≥98%

    Description: MLN9708 (also known as ixazomib citrate; MLN-9708; trade name Ninlaro) is a prodrug of Ixazomib (MMLN-2238) which is an orally bioavailable and 2nd generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN9708 is hydrolyzed to the biologically active form, MLN2238, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, it is less potent to β1 and little activity to β2. MLN9708 exhibits excellent antitumor activity in both solid tumor and hematologic preclinical xenograft models.

    References: Cancer Res. 2010 Mar 1;70(5):1970-80; Clin Cancer Res. 2011 Aug 15;17(16):5311-21.

    Related CAS #: 1239908-20-3 (citrate)   1201902-80-8   1072833-77-2 (free)       

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)517.12
    FormulaC20H23BCl2N2O9
    CAS No.1201902-80-8
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 100 mg/mL (193.4 mM)
    Water: <1 mg/mL
    Ethanol: <1 mg/mL
    Solubility (In vivo)0.5% hydroxyethyl cellulose: 30 mg/mL
    Synonyms

    Synonym: MLN9708; MLN-9708; MLN 9708; ixazomib citrate; MMLN-2238-prodrug; MMLN 2238-prodrug; MMLN2238-prodrug; Ixazomib-prodrug; Ninlaro.

    Chemical Name: 4-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid

    InChi Key: YTXSYWAKVMZICI-PVCZSOGJSA-N

    InChi Code: InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-17(29)8-20(34-21,19(31)32)7-16(27)28)25-15(26)9-24-18(30)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,30)(H,25,26)(H,27,28)(H,31,32)/t14-,20?/m0/s1

    SMILES Code: O=C(C(C1)(CC(O)=O)OB([[email protected]@H](NC(CNC(C2=CC(Cl)=CC=C2Cl)=O)=O)CC(C)C)OC1=O)O


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: MLN9708 is a selective, orally bioavailable, second-generation proteasome inhibitor. MLN9708 has a shorter proteasome dissociation half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib, which we believe plays an important role in its improved tissue distribution. MLN9708 has a larger blood volume distribution at steady state, and analysis of 20S proteasome inhibition and markers of the unfolded protein response confirms that MLN9708 has greater pharmacodynamic effects in tissues than bortezomib. MLN9708 is a second-generation small-molecule proteasome inhibitor being developed for the treatment of a broad range of human malignancies. Upon exposure to aqueous solutions or plasma, MLN9708 rapidly hydrolyzes to its biologically active form MLN2238. MLN2238 is the biologically active form of MLN9708.


    Kinase Assay: Calu-6 cells are cultured in MEM containing 10% fetal bovine serum and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. Proteasome activity is assessed by monitoring hydrolysis of the chymotrypsin-like substrate Suc-LLVY-aminoluciferin in the presence of luciferase using the Proteasome-Glo assay reagents according to the manufacturer's instructions. Luminescence is measured using a LEADseeker instrument.


    Cell Assay: Calu-6 cells are cultured in MEM containing 10% FBS and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. For IC50 determinations, cells are treated with varying concentrations of Bortezomib or MLN2238 in DMSO (0.5% final, v/v) for 1 hour at 37 °C. For reversibility experiments, cells are treated with either 1 μM Bortezomib or MLN2238 for 30 minutes at 37 °C and then washed thrice in medium to remove the Bortezomib or MLN2238. Cells are incubated for an additional 4 hours at 37 °C, after which the medium is removed and replaced with fresh medium.

    In VivoMLN9708 shows superior antitumor activity in both solid tumor and hematologic preclinical xenograft models when administered via multiple dosing routes and regimens. Recent preclinical pharmacology studies shows that MLN9708 has a shorter proteasome dissociation half-life than bortezomib, as well as improved pharmacokinetics, pharmacodynamics, and antitumor activity in xenograft models. MLN9708 has shown antitumor efficacy in a wide range of tumor xenografts.
    Animal modelCB-17 SCID mice are subcutaneously inoculated with MM.1S cells
    Formulation & DosageDissolved in 5% 2-hydroxypropyl-β-cyclodextrin; 11 mg/kg; i.v. injection
    References

    Cancer Res. 2010 Mar 1;70(5):1970-80; Clin Cancer Res. 2011 Aug 15;17(16):5311-21.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    MLN9708

    Proteasome inhibitor MLN2238 is structurally distinct from bortezomib, and inhibits proteasome activity in vitro. Clin Cancer Res. 2011 Aug 15;17(16):5311-21. 
     
     

    MLN9708

    MLN2238 inhibits growth of xenografted human MM cells in CB-17 SCID mice. Clin Cancer Res. 2011 Aug 15;17(16):5311-21.
     

    MLN9708

    Mechanisms mediating anti-MM activity of MLN2238. Clin Cancer Res. 2011 Aug 15;17(16):5311-21.

    MLN9708

    MLN9708

    MLN9708


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?